NCT06643390 is a Phase 1 clinical trial of MK-2225 in Systemic Sclerosis, sponsored by Merck Sharp & Dohme LLC.

Who is sponsoring NCT06643390?

NCT06643390 is sponsored by Merck Sharp & Dohme LLC.

What drugs are being tested in NCT06643390?

Interventions in NCT06643390: MK-2225, Placebo.

What condition does NCT06643390 study?

NCT06643390 studies Systemic Sclerosis.

Is NCT06643390 still recruiting?

NCT06643390 is currently completed. Last updated 29 July 2025.

Last reviewed 2025-07-29 · How we verify

NCT06643390

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of MK-2225 in Healthy Participants (MK-2225-003)

Completed Phase 1 Last updated 29 July 2025

What this trial tests

Phase 1 trial testing MK-2225 in Systemic Sclerosis in 32 participants. Completed in 14 July 2025.

Timeline

21 November 2023

Primary endpoint
14 July 2025

14 July 2025

Quick facts

Lead sponsor	Merck Sharp & Dohme LLC
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	double
Primary purpose	treatment
Enrollment	32
Start date	21 November 2023
Primary completion	14 July 2025
Estimated completion	14 July 2025
Sites	2 locations across United States

Drugs / interventions tested

MK-2225 — full drug profile →
Placebo

Conditions studied

Systemic Sclerosis — all drugs for Systemic Sclerosis →

Sponsor

Merck Sharp & Dohme LLC — full company profile →

Who can join

Adults 18 to 55, any sex, with Systemic Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to learn about the safety of MK-2225, including how well people tolerate it. Researchers also want to learn what happens to different doses of MK-2225 in a person's body over time.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of MK-2225

Trials testing the same drug.

NCT04948554 — A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-222 · Phase 1 · terminated

Other recruiting trials for Systemic Sclerosis

Currently open trials in the same condition.

NCT07335562 — A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versu · Phase 3 · recruiting
NCT06947473 — Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH. · Phase 1, PHASE2 · recruiting
NCT07047690 — A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis · Phase 2 · recruiting
NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
NCT07295847 — A Study of AZD0120 in Autoimmune Diseases · Phase 1 · recruiting

Other Merck Sharp & Dohme LLC trials

Trials by the same sponsor.

NCT07224477 — A Clinical Study of V540A in Healthy Female Participants (V540A-005) · Phase 2 · not yet recruiting
NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07528508 — A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadone (MK-8527 · Phase 1 · not yet recruiting
NCT07513376 — A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (M · Phase 3 · not yet recruiting
NCT07532304 — A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Parti · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06643390 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Merck Sharp & Dohme LLC
Last refreshed: 29 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06643390.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing